Compare iShares Global Clean Energy ETF (ICLN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Global Clean Energy ETF trades at $18.43, while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ICLN | XBI | |
|---|---|---|
52-Week High | $23.75 | $164.28 |
52-Week Low | $13.66 | $86.92 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN, the iShares Global Clean Energy ETF, trades at $18.41, up 1.83% today, but technical indicators signal a bearish trend with moving averages and overall momentum pointing lower. The fund provides exposure to 105 global renewable energy companies, though key valuation and profitability ratios are not publicly disclosed for the ETF itself. Recent news highlights strong 2026 performance with over 25% gains, driven by global energy security concerns and data center power demand, though it faces competition from traditional energy ETFs offering lower fees and higher yields.
The outlook for ICLN is mixed; clean energy tailwinds from policy support and electrification trends offer growth potential, but risks include regulatory hurdles, fee competitiveness, and volatility. Analyst sentiment is cautious due to fee comparisons and policy dependence, with institutional interest balanced against outperformance of alternatives like uranium ETFs. Investment suitability hinges on appetite for clean energy sector volatility versus stable income.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
